← Leaderboards
Mohamad Imad Damaj
Virginia Commonwealth University
$10,091,132
Attributed
$17,792,414
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,792,414 · 13
By mechanism
R01$11,999,903 · 7
U01$2,667,634 · 1
R61$1,179,675 · 1
P50$767,037 · 1
R25$525,283 · 1
U19$471,434 · 1
Top collaborators
- Michael F. Miles11 shared
- David A. Gewirtz9 shared
- Elizabeth Edmondson5 shared
- Vivek Kumar5 shared
- Camron D Bryant4 shared
- Dana E Selley3 shared
- Laura J Sim-Selley3 shared
- Devanand Sarkar1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Darlene H Brunzell$3,114,387
- Elizabeth Edmondson$624,688
- Vijay Lyall$3,974,422
- Elizabeth W Edmondson$816,423
- Joseph William Landry$2,951,878
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMouse ModelMediatingPredispositionNeuronsAnimal ModelAcuteBehaviorPharmaceutical PreparationsGeneticNicotineGenesDoseQuantitative Trait LociCandidate Disease GeneTraitPhenotypeMapsPathway InteractionsTissuesTherapy DevelopmentComplexBehavioralPain
Grant awards (55)
Targeting Sphingosine-1-phosphate (S1P1) receptors for the treatment of Aromatase Inhibitors-induced Musculoskeletal Symptoms$626,434
R01 · FY2025 · CA · contact PI
Inhibition of NLRP3 inflammasome for the treatment of Chemotherapy-induced peripheral neuropathy$181,448
R21 · FY2025 · CA · contact PI
VCU Health Education Opportunities for Teachers (HERO-T)$104,664
R25 · FY2025 · DA
Targeting Sphingosine-1-phosphate (S1P1) receptors for the treatment of Aromatase Inhibitors-induced Musculoskeletal Symptoms$598,671
R01 · FY2024 · CA · contact PI
VCU Health Education Opportunities for Teachers (HERO-T)$104,664
R25 · FY2024 · DA
Targeting Sphingosine-1-phosphate (S1P1) receptors for the treatment of Aromatase Inhibitors-induced Musculoskeletal Symptoms$613,882
R01 · FY2023 · CA · contact PI
Identification of gene variants for alcohol analgesia$458,846
R01 · FY2023 · AA · contact PI
VCU Health Education Opportunities for Teachers (HERO-T)$104,664
R25 · FY2023 · DA
Initial Development of AEG-1 inactivation as a possible strategy for pain treatment$1,179,675
R61 · FY2022 · NS · contact PI
Genetic basis of nicotine withdrawal in a reduced complexity cross$554,190
U01 · FY2022 · DA · contact PI
Identification of gene variants for alcohol analgesia$460,260
R01 · FY2022 · AA · contact PI
VCU Health Education Opportunities for Teachers (HERO-T)$104,664
R25 · FY2022 · DA
Genetic basis of nicotine withdrawal in a reduced complexity cross$554,190
U01 · FY2021 · DA · contact PI
Identification of gene variants for alcohol analgesia$516,760
R01 · FY2021 · AA · contact PI
Genetic basis of chemotherapy-induced neuropathy in a reduced complexity cross$375,571
R01 · FY2021 · CA · contact PI
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy$259,419
R01 · FY2021 · CA · contact PI
VCU Health Education Opportunities for Teachers (HERO-T)$106,627
R25 · FY2021 · DA
Genetic basis of nicotine withdrawal in a reduced complexity cross$585,690
U01 · FY2020 · DA · contact PI
Identification of gene variants for alcohol analgesia$482,967
R01 · FY2020 · AA · contact PI
Genetic basis of chemotherapy-induced neuropathy in a reduced complexity cross$446,100
R01 · FY2020 · CA · contact PI
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$342,604
R01 · FY2020 · CA
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy$324,275
R01 · FY2020 · CA · contact PI
Project 3: Adolescent Nicotine$150,431
P50 · FY2020 · DA · contact PI
Genetic basis of nicotine withdrawal in a reduced complexity cross$495,812
U01 · FY2019 · DA · contact PI
Genetic basis of chemotherapy-induced neuropathy in a reduced complexity cross$416,028
R01 · FY2019 · CA · contact PI
Identification of gene variants for alcohol analgesia$392,968
R01 · FY2019 · AA · contact PI
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$332,443
R01 · FY2019 · CA
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy$314,547
R01 · FY2019 · CA · contact PI
Project 3: Adolescent Nicotine$152,101
P50 · FY2019 · DA · contact PI
Genetic basis of nicotine withdrawal in a reduced complexity cross$477,752
U01 · FY2018 · DA · contact PI
Genetic basis of chemotherapy-induced neuropathy in a reduced complexity cross$442,176
R01 · FY2018 · CA · contact PI
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$342,846
R01 · FY2018 · CA
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy$281,441
R01 · FY2018 · CA · contact PI
Project 3: Adolescent Nicotine$156,102
P50 · FY2018 · DA · contact PI
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$342,964
R01 · FY2017 · CA
Genes and molecular pathways in nicotine dependence and withdrawal$305,000
R01 · FY2017 · DA · contact PI
Project 3: Adolescent Nicotine$135,012
P50 · FY2017 · DA · contact PI
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$363,112
R01 · FY2016 · CA
Genes and molecular pathways in nicotine dependence and withdrawal$301,950
R01 · FY2016 · DA · contact PI
Project 3: Adolescent Nicotine$173,391
P50 · FY2016 · DA · contact PI
Genes and molecular pathways in nicotine dependence and withdrawal$382,733
R01 · FY2015 · DA · contact PI
Genes and molecular pathways in nicotine dependence and withdrawal$305,000
R01 · FY2014 · DA · contact PI
Genes and molecular pathways in nicotine dependence and withdrawal$83,562
R01 · FY2014 · DA · contact PI
Genes and molecular pathways in nicotine dependence and withdrawal$304,417
R01 · FY2013 · DA · contact PI
Role of calcium-dependent mechanisms in nicotine's tolerance and effects$210,552
R01 · FY2010 · DA · contact PI
Role of calcium-dependent mechanisms in nicotine's tolerance and effects$212,678
R01 · FY2009 · DA · contact PI
Evaluation of Buproprion in Nicotine Dependence Model$171,511
U19 · FY2009 · DA · contact PI
Role of calcium-dependent mechanisms in nicotine's tolerance and effects$212,678
R01 · FY2008 · DA · contact PI
Evaluation of Buproprion in Nicotine Dependence Model$156,574
U19 · FY2008 · DA · contact PI
Role of calcium-dependent mechanisms in nicotine's tolerance and effects$217,019
R01 · FY2007 · DA · contact PI
Evaluation of Buproprion in Nicotine Dependence Model$143,349
U19 · FY2007 · DA · contact PI
Role of calcium-dependent mechanisms in nicotine's tolerance and effects$186,250
R01 · FY2006 · DA · contact PI
CALCIUM-DEPENDENT MECHANISMS IN NICOTINE'S TOLERANCE$181,250
R01 · FY2003 · DA
CALCIUM-DEPENDENT MECHANISMS IN NICOTINE'S TOLERANCE$181,250
R01 · FY2002 · DA
CALCIUM-DEPENDENT MECHANISMS IN NICOTINE'S TOLERANCE$181,250
R01 · FY2001 · DA